Epitopea Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 46

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $31M

  • Investors
  • 15

Epitopea General Information

Description

Developer of transatlantic cancer immunotherapeutics designed to target a novel class of tumor-specific antigens. The company's technology builds on its proprietary approach to identify shared, expressed tumor-specific antigens and develop immunotherapies that are anticipated to kill malignant cells while sparing non-cancerous cells, enabling healthcare providers to cure cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication with minimal side effects and durable benefits.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom

Epitopea Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epitopea Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series A) 24-Oct-2024 $31M Completed Generating Revenue
5. Grant 12-Sep-2024 Completed Generating Revenue
4. Grant 13-Apr-2023 Completed Generating Revenue
3. Seed Round 25-Apr-2022 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2021 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Epitopea’s complete valuation and funding history, request access »

Epitopea Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed Preferred
To view Epitopea’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Epitopea Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of transatlantic cancer immunotherapeutics designed to target a novel class of tumor-specific antigens. The co
Drug Discovery
Cambridge, United Kingdom
46 As of 2025

Oxford, United Kingdom
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Epitopea Competitors (4)

One of Epitopea’s 4 competitors is Enara Bio, a Venture Capital-Backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enara Bio Venture Capital-Backed Oxford, United Kingdom
Agenus Formerly VC-backed Lexington, MA
Eleven Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Bicycle Therapeutics Formerly VC-backed Cambridge, United Kingdom
To view Epitopea’s complete competitors history, request access »

Epitopea Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epitopea Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Investissement Quebec PE/Buyout Minority
IRICoR Corporation Minority
Angel (individual) Minority
Meltwind Advisory Venture Capital Minority
Innovate UK Government
You’re viewing 5 of 15 investors. Get the full list »

Epitopea FAQs

  • When was Epitopea founded?

    Epitopea was founded in 2021.

  • Where is Epitopea headquartered?

    Epitopea is headquartered in Cambridge, United Kingdom.

  • What is the size of Epitopea?

    Epitopea has 46 total employees.

  • What industry is Epitopea in?

    Epitopea’s primary industry is Drug Discovery.

  • Is Epitopea a private or public company?

    Epitopea is a Private company.

  • What is Epitopea’s current revenue?

    The current revenue for Epitopea is .

  • How much funding has Epitopea raised over time?

    Epitopea has raised $44.4M.

  • Who are Epitopea’s investors?

    Investissement Quebec, IRICoR, , Meltwind Advisory, and Innovate UK are 5 of 15 investors who have invested in Epitopea.

  • Who are Epitopea’s competitors?

    Enara Bio, Agenus, Eleven Therapeutics, and Bicycle Therapeutics are competitors of Epitopea.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process